Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy.
Shaikh
Saad
S
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006450:Hemoglobin SC Disease / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014823:Vitreous Hemorrhage / Q000188:drug therapy / Q000209:etiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab